Choroidal melanoma treatment shows promising early results in phase 1b/2 trial

Source: Healio, June 2018

Light-activated AU-011 for the treatment of primary choroidal melanoma was well tolerated with no severe adverse events, while showing promising early efficacy results, in a phase 1b/2 trial, Aura Biosciences announced in a press release.

The open-label, multicenter trial is evaluating the safety and efficacy of single and multiple ascending doses of AU-011 in 30 adult patients with small to medium primary choroidal melanoma.